Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis

PHASE3CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

November 15, 2019

Primary Completion Date

September 2, 2022

Study Completion Date

September 26, 2022

Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
DRUG

Oltipraz

Total 90mg, By mouth, TID

DRUG

Placebos

Total 90mg, By mouth, TID

Trial Locations (21)

49201

Dong-A University Hospital, Busan

411-706

Inje University Ilsan Paik Hospital, Goyang-si

Unknown

The Catholic University of Korea, Uijeongbu ST. Mary's Hospital, Uijeongbu-si

Inha University Hospital, Incheon

Catholic University Bucheon ST. Mary's Hospital, Bucheon-si

Soonchunhyang University Bucheon Hospital, Bucheon-si

Keimyung University Dongsan Medical Center, Daegu

Gangneung Asan Medical Center, Gangneung-si

Chung-Ang University Hosptial, Seoul

Hallym University Gangnam Sungsim Hospital, Seoul

Hanyang University Hospital, Seoul

Korea University Guro Hospital, Seoul

National Medical Center, Seoul

Severance Hospital, Seoul

Soonchunhyang University Seoul Hospital, Seoul

Yonsei University Gangnam Severance Hospital, Seoul

Ajou University School of Medicine, Suwon

Wonju Severance Christian Hospital, Wanju

410-719

NHUS Ilsan Hospital, Goyang-si

110-744

Seoul National University Hospital, Seoul

156-707

Boramae Hospital, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

PharmaKing

INDUSTRY